All news

Pomerantz probes Tyra Biosciences over securities fraud claims

Alpha Vantage · PR Newswire · · AI-summarised by FinFlash

Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences, Inc. following a sharp decline in the company's share price. The probe follows a September 9, 2026 announcement of initial Phase 2 results for Tyra's drug dabogratinib, which reported Grade 3 treatment-emergent adverse events in a notable percentage of participants despite being described as having a favorable safety profile. The news sent Tyra shares down 17.66%, prompting the firm to examine potential unlawful business practices by officers and/or directors.

Read original source

TYRA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.